<DOC>
	<DOCNO>NCT02319369</DOCNO>
	<brief_summary>This Phase 1 , open-label study DS-3032b ass safety tolerability identify Maximum Tolerated Dose ( MTD ) /tentative Recommended Phase II Dose ( RP2D ) subject refractory relapse Acute Myelogenous Leukemia ( AML ) , Acute Lymphocytic Leukemia ( ALL ) , Chronic Myelogenous Leukemia ( CML ) blast phase , high risk MDS Part 1-Dose Escalation refractory relapse AML high risk Myelodysplastic Syndrome ( MDS ) Part 2-Dose Expansion .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability Pharmacokinetics DS-3032b Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>Has one follow diagnosis : Subjects must refractory relapse AML ALL , CML blast phase , high risk MDS ( define Revised International Prognostic Scoring System [ IPSSR ] score High Very High inclusion Part 1 study . Subjects must refractory relapsed AML highrisk MDS ( define IPSSR score High Very High inclusion Part 2 study . Man woman &gt; = 18 year old . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Has adequate renal function , define : Creatinine clearance &gt; =60 mL/min , calculate use modify Cockcroft Gault equation , ( [ { 140 age year } × { actual weight kg } ] divide [ { 72 × serum creatinine mg/dL } multiply 0.85 female ] ) , OR creatinine = &lt; 1.5 X ULN Has adequate hepatic function , define : AST/ALT = &lt; 3 X ULN ; Bilirubin = &lt; 1.5 X ULN , unless result hemolysis Has adequate blood clot function , define : International normalize ratio activate partial thromboplastin time = &lt; 1.5 XULN Subject able provide write informed consent , comply protocol visit procedure , take oral medication , active infection comorbidity would interfere therapy . Subject ( male female ) childbearing/ reproductive potential must agree use double barrier contraceptive measure avoid intercourse study 90 day last dose study drug . Subject must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) . Subject must sign date Institutional Review Boardapproved inform consent form ( include Health Insurance Portability Accountability Act authorization , applicable ) performance studyspecific procedure test . Able willing provide bone marrow biopsies/aspirates request protocol . Is willing undergo malignancy genotyping TP53 gene mutation , insertion , deletion screening . Has life expectancy least 3 month . Has diagnosis acute promyelocytic leukemia . Has malignancy contain non synonymous mutation , insertion , deletion TP53 gene determine previously screen . Presence central nervous system involvement leukemia history primary central nervous system leukemia . Has second concurrent primary malignancy require active treatment within previous 2 year , except localize cancer apparently cure , nonmelanoma skin cancer , superficial bladder cancer , carcinoma situ cervix breast . Any condition would preclude adequate absorption DS3032b , include refractory nausea vomiting , malabsorption , biliary shunt , significant bowel resection , and/or graftversushost disease ( GVHD ) affect gut . Has uncontrolled infection require intravenous antibiotic , antiviral , antifungal , know human immunodeficiency virus infection , active hepatitis B C infection . Has concomitant medical condition would opinion Investigator increase risk toxicity . Has unresolved toxicity previous anticancer therapy , define toxicity ( alopecia ) yet resolve NCICTCAE v4 , Grade = &lt; 1 baseline . Subjects chronic Grade 2 toxicity may eligible per discretion Investigator Sponsor ( eg , Grade 2 chemotherapyinduced neuropathy ) . Has receive Hematopoietic Stem Cell Transplantation ( HSCT ) within 60 day first dose DS3032b , immunosuppressive therapy postHSCT time screening , clinically significant GVHD ( use topical steroid ongoing skin GVHD permit ) . Subjects must washout period &gt; =2 week least 4 halflives last systemic immunosuppressive treatment GVHD . Is receive concomitant treatment strong inhibitor inducer CYP3A4/5 . Received therapy intend treat malignancy within 21 day first receipt DS3032b ( except hydroxyurea , must discontinue least 48 hour prior study treatment ) . Had major surgery within 4 week prior study drug treatment . Participated therapeutic clinical study within 3 week study drug treatment , current participation therapeutic investigational procedure . Prolongation correct QT interval Fridericia 's method ( QTcF ) rest , mean QTcF interval &gt; 450 m male &gt; 470 m female base triplicate electrocardiogram ( ECGs ) . Pregnant breastfeeding . Substance abuse medical , psychological , social condition , opinion Investigator , may interfere subject 's participation clinical study evaluation clinical study result . Prior treatment MDM2 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>